Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956473 · ClinicalTrials.gov registry record · NA
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT02956473 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 57 participants.
The verdict
NCT02956473, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the patient in a new position (lying on one's back) as opposed to in the standard position (lying on one's stomach).
Interventions
- DEVICE Ultrasound
- PROCEDURE Standard of Care
- DEVICE Mammography
- DEVICE Supine MRI
- OTHER Neoadjuvant Therapy (NAT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2022-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956473
The ClinicalTrials.gov registry entry for NCT02956473 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ultrasound is the first listed.
NCT02956473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956473 about?
NCT02956473 is a clinical study titled "Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy". This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the patient in a new position (lying on one's back) as opposed to in the stand...
What is the current status of trial NCT02956473?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2016-11-15. Estimated completion is 2022-08.
What interventions are being tested in trial NCT02956473?
The interventions under investigation include: Ultrasound (DEVICE), Standard of Care (PROCEDURE), Mammography (DEVICE), Supine MRI (DEVICE), Neoadjuvant Therapy (NAT) (OTHER).
Who is sponsoring clinical trial NCT02956473?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.